TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31158260

Group type: EXPERIMENTAL
Intervention: Various randomization procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Log-rank test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 0
Study: 27500463

Group type: EXPERIMENTAL
Intervention: Sativex® treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 26471236

Group type: EXPERIMENTAL
Intervention: Polyphenon E 200 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Polyphenon E 400 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Polyphenon E 600 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 26158157

Group type: EXPERIMENTAL
Intervention: Pyridoxine (60 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (without pyridoxine)
Number of subjects: 60
Study: 23020850

Group type: EXPERIMENTAL
Intervention: Belly dance (16 weeks, twice a week)
Number of subjects: 80
Study: 19053980

Group type: EXPERIMENTAL
Intervention: 3.5 g/d prebiotic
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 7 g/d prebiotic
Number of subjects: 44

Group type: COMPARATOR
Intervention: 7 g/d placebo
Number of subjects: 44
Study: 17410063

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty/stenting (CAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised trials
Number of subjects: 0
Study: 15068719

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH) combined with conventional therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 37
Study: 11879209

Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 unit x kg(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (healthy adult patients without hepatic cirrhosis)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cirrhosis/saline
Number of subjects: 30
Study: 9850013

Group type: EXPERIMENTAL
Intervention: 0.5 mg transbuccal melatonin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8272296

Group type: EXPERIMENTAL
Intervention: Deep en bloc closure
Number of subjects: 23

Group type: COMPARATOR
Intervention: Superficial skin closure
Number of subjects: 23
Study: 2531117

Group type: EXPERIMENTAL
Intervention: Single-dose spectinomycin (TRO: 2 g intramuscularly)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Aqueous procaine penicillin G (APPG: 4.8 x 10(6) units) plus 1 g of probenecid
Number of subjects: 400

Group type: COMPARATOR
Intervention: Aqueous procaine penicillin G (APPG)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Single-dose spectinomycin (TRO)
Number of subjects: 400
Study: 30554932

Group type: EXPERIMENTAL
Intervention: Ultrasound guided ankle block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metatarsal block
Number of subjects: 50
Study: 31409342

Group type: EXPERIMENTAL
Intervention: Intervention group (n=217)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Control group (n=218)
Number of subjects: 633
Study: 28034484

Group type: EXPERIMENTAL
Intervention: GEB application with McGRATH
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GEB application with AWS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GEB application with McL
Number of subjects: 16

Group type: COMPARATOR
Intervention: McGRATH without GEB
Number of subjects: 16

Group type: COMPARATOR
Intervention: AWS without GEB
Number of subjects: 16

Group type: COMPARATOR
Intervention: McL without GEB
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: McGRATH with GEB
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AWS with GEB
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: McL with GEB
Number of subjects: 16
Study: 26480938

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 120
Study: 23391516

Group type: EXPERIMENTAL
Intervention: Training attention toward threat
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 34
Study: 21699484

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 25 mg once daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 75 mg once daily
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 150 mg once daily
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 19130936

Group type: EXPERIMENTAL
Intervention: 4 group sessions led by a community social worker and 6 home visits by community health workers
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mailed asthma education materials
Number of subjects: 42
Study: 17346524

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Abdominal myomectomy
Number of subjects: 25
Study: 15380912

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (3 x 125 ml, 2.38 MJ/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (similar amounts of a non-caloric fluid)
Number of subjects: 56
Study: 11808987

Group type: EXPERIMENTAL
Intervention: Spa therapy for 3 weeks
Number of subjects: 102
Study: 9756115

Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy (total dose 1050 mg over seven consecutive dialysis sessions and supplemental monthly doses)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy
Number of subjects: 22
Study: 7848600

Group type: EXPERIMENTAL
Intervention: HIV-2
Number of subjects: 469

Group type: COMPARATOR
Intervention: HIV-1
Number of subjects: 469
Study: 2899188

Group type: EXPERIMENTAL
Intervention: Low-fat high-carbohydrate diet (15% of calories from fat, increased complex carbohydrates)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (general dietary advice)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intervention group (low-fat diet)
Number of subjects: 21
Study: 30654852

Group type: EXPERIMENTAL
Intervention: Behavioural sleep intervention (two sessions covering sleep hygiene and standardized behavioral strategies)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Behavioural sleep intervention
Number of subjects: 244
Study: 30664454

Group type: EXPERIMENTAL
Intervention: Fall TIPS modalities (EHR version, laminated paper version, bedside display version)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Fall TIPS modalities
Number of subjects: 1209
Study: 28042880

Group type: EXPERIMENTAL
Intervention: Written information about the complications of postoperative pain
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Additional pain education for nurses
Number of subjects: 760
Study: 25559730

Group type: EXPERIMENTAL
Intervention: Probiotic administration (twice daily, initiated within 10 days of burn until wound closure)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Probiotic administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administration (twice daily, initiated within 10 days of burn until wound closure)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study: 23690087

Group type: EXPERIMENTAL
Intervention: Self-Management Program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 104
Study: 21768631

Group type: EXPERIMENTAL
Intervention: Operative repair using an open technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-operative treatment in a cast
Number of subjects: 80
Study: 17525793

Group type: EXPERIMENTAL
Intervention: Evidence-based message system presenting real-time evidence to providers
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 44
Study: 16274054

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Photosense, 0.05 mg/kg, performed on day 3 after administration, using a laser at 675 nm and a light dose of 120 J/cm2
Number of subjects: 15
Study: 12420854

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (2 g/200 mg)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Cefotaxime (2 g)
Number of subjects: 476
Study: 9452274

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 500 mg, twice daily for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 8573993

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0
Study: 1973843

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 41

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 41
Study: 791564

Group type: EXPERIMENTAL
Intervention: Methyldopa administered once at bedtime (HS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Methyldopa administered three times daily (TID)
Number of subjects: 14
Study: 30734702

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) - hyperproteic low in colecistokinetics diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (nothing by mouth)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 19
Study: 26475248

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Landmark
Number of subjects: 1189
Study: 25300706

Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2.0‐3.5)
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Aspirin 325 mg
Number of subjects: 2305
Study: 22486342

Group type: EXPERIMENTAL
Intervention: Aerobic endurance training (AET) - 10 weeks, 30-50 min cycling at 70%-75% maximal heart rate
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) - 10 weeks, 2-4 sets × 8-10 repetitions of 5-7 exercises at 70%-75% 1 repetition maximum
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (CON) - non-exercising condition
Number of subjects: 102
Study: 20460257

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Field exercise challenge
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Any stimulus
Number of subjects: 58
Study: 18077494

Group type: EXPERIMENTAL
Intervention: 0.5% sodium nitroprusside (NaNP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1% acetylcholine chloride (ACh)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 min treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 min treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: NaNP vs ACh
Number of subjects: 8
Study: 15849813

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch anastomosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Straight coloanal anastomosis (CAA)
Number of subjects: 50
Study: 14621036

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no esmolol)
Number of subjects: 30
Study: 10919681

Group type: EXPERIMENTAL
Intervention: CFC pressurized metered dose inhaler (pMDI; Ventolin)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: HFA 134a pMDI (Ventolin CFC-free)
Number of subjects: 423
Study: 8816621

Group type: EXPERIMENTAL
Intervention: Luteal support with oral E2 (2 mg three times daily) and vaginal P (100 mg twice daily) starting on the day of retrieval and ET
Number of subjects: 93

Group type: COMPARATOR
Intervention: No luteal support (control group)
Number of subjects: 93
Study: 1566953

Group type: EXPERIMENTAL
Intervention: Mailed psychoeducational materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no psychoeducational materials)
Number of subjects: 0
Study: 4050728

Group type: EXPERIMENTAL
Intervention: Iron treatment (30 mg iron as ferrous sulfate given before a meal)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study: 31599200

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alirocumab with ODYSSEY LONG TERM data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alirocumab with FOURIER data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alirocumab with FOURIER data (50% weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alirocumab with FOURIER data (10% weight)
Number of subjects: 0
Study: 29377755

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 658

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 658
Study: 25840585

Group type: EXPERIMENTAL
Intervention: Probiotic lozenge containing two strains of Lactobacillus reuteri, taken once daily for 17 months.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo lozenge without active bacteria, taken once daily for 17 months.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups (probiotic and placebo)
Number of subjects: 85
Study: 24511017

Group type: EXPERIMENTAL
Intervention: YAP1 activation gene expression signature
Number of subjects: 267
Study: 22219013

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab (400 mg/m2 day 1, followed by 250 mg/m2 weekly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 100

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 100
Study: 20426859

Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) with CPAP of 40 cmH2O over 30 seconds
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no RM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 18598605

Group type: EXPERIMENTAL
Intervention: Single embryo transfer (SET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double embryo transfer (DET)
Number of subjects: 0
Study: 16283062

Group type: EXPERIMENTAL
Intervention: Progressive strength training exercise program
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 167
Study: 12131236

Group type: EXPERIMENTAL
Intervention: Cognitive coping intervention
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Expression intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 10504181

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tissue plasminogen activator
Number of subjects: 0
Study: 9117477

Group type: EXPERIMENTAL
Intervention: Supported education program participants
Number of subjects: 0
Study: 2058557

Group type: EXPERIMENTAL
Intervention: Sotalol (1.5 mg/kg over 10 minutes)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 6352951

Group type: EXPERIMENTAL
Intervention: Stress management training plus relaxation imagery
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Relaxation imagery alone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Weekly blood pressure checks
Number of subjects: 34
Study: 30678553

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 5504

Group type: COMPARATOR
Intervention: Pembrolizumab alone
Number of subjects: 5504

Group type: EXPERIMENTAL
Intervention: Combination therapy (Pembrolizumab plus chemotherapy)
Number of subjects: 5504
Study: 26946735

Group type: EXPERIMENTAL
Intervention: Slow twisting needle insertion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tubing needle insertion
Number of subjects: 100
Study: 24125846

Group type: EXPERIMENTAL
Intervention: PAA+/PSC+ hospitals
Number of subjects: 400000

Group type: EXPERIMENTAL
Intervention: PAA+/PSC- hospitals
Number of subjects: 400000

Group type: EXPERIMENTAL
Intervention: PAA-/PSC+ hospitals
Number of subjects: 400000

Group type: COMPARATOR
Intervention: PAA-/PSC- hospitals
Number of subjects: 400000
Study: 21623216

Group type: EXPERIMENTAL
Intervention: Minimal educational intervention
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control
Number of subjects: 186
Study: 19228151

Group type: EXPERIMENTAL
Intervention: Withdrawal therapy followed by neurologist (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Withdrawal therapy followed by primary care physician (group B)
Number of subjects: 80
Study: 16297576

Group type: EXPERIMENTAL
Intervention: Soy-rich diet (25 g soy protein, >50 mg/day isoflavones)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Soy-free diet (control diet)
Number of subjects: 36
Study: 15330019

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) combined with intermittent pneumatic compression
Number of subjects: 131

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) combined with graduated compression stockings
Number of subjects: 131
Study: 11200857

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (eight sessions) followed by outpatient treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Patients who dropped out of outpatient treatment
Number of subjects: 88
Study: 9294113

Group type: EXPERIMENTAL
Intervention: Alendronate (5 to 20 mg/d)
Number of subjects: 231
Study: 8112205

Group type: EXPERIMENTAL
Intervention: DHEP plaster (180 mg, applied b.i.d. for 14 days)
Number of subjects: 190

Group type: COMPARATOR
Intervention: DDA emulgel (1.16%, applied q.i.d. for 14 days)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 190
Study: 3106210

Group type: EXPERIMENTAL
Intervention: High fat load (3 g/kg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medium fat dosage (1.5 g/kg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Only carbohydrates (as caloric source)
Number of subjects: 30
Study: 31713079

Group type: EXPERIMENTAL
Intervention: Planning + education
Number of subjects: 102

Group type: COMPARATOR
Intervention: Education only
Number of subjects: 102
Study: 29196184

Group type: EXPERIMENTAL
Intervention: Binocular iPad game prescribed for 1 hour per day (n=40)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Part-time patching of the fellow eye prescribed for 2 hours per day (n=60)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of binocular iPad game vs patching
Number of subjects: 100
Study: 27382543

Group type: EXPERIMENTAL
Intervention: Aloe vera mouthwash
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthwash
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (flavored distilled water)
Number of subjects: 90
Study: 24496312

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (H-CHO) diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-fat (H-FAT) diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Feeding (after fasting)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Fasting (before feeding)
Number of subjects: 7
Study: 22969068

Group type: EXPERIMENTAL
Intervention: Ortho-k lenses
Number of subjects: 102

Group type: COMPARATOR
Intervention: Single-vision glasses
Number of subjects: 102
Study: 20576182

Group type: EXPERIMENTAL
Intervention: Gang involvement at age 13 to 14
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Deviancy training with friends at age 16 to 17
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Violence by age 18 to 19
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Indirect and direct path between early adolescent gang involvement and later violence
Number of subjects: 998
Study: 17765013

Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 19595361

Group type: EXPERIMENTAL
Intervention: Post-PCI ECG T-wave amplitude
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Net decrease in T-wave amplitude during reperfusion therapy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Large T-wave amplitudes in static pre- and post-PCI ECGs
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Dynamic development of more negative T waves during PCI
Number of subjects: 207
Study: 15007652

Group type: EXPERIMENTAL
Intervention: Limonene oxidation products (LOPs)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitrate radicals (NO(3))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Residual reactants
Number of subjects: 8

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 8
Study: 12075385

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UH)
Number of subjects: 70
Study: 9598491

Group type: EXPERIMENTAL
Intervention: 50 mg oral sertraline
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chronic open label treatment with sertraline
Number of subjects: 37
Study: 7873461

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks
Number of subjects: 295

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus pamidronate (Aredia)
Number of subjects: 295
Study: 3285485

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 120 mg/d plus diethylstilbestrol (DES) 0.1 to 3 mg/d
Number of subjects: 81

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) 0.1 to 3 mg/d
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Megestrol acetate plus minidose DES
Number of subjects: 81

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 81
Study: 11557459

Group type: EXPERIMENTAL
Intervention: IDV-RTV 800-100 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: IDV-RTV 800-200 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: IDV-RTV 400-400 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo of IDV with RTV 100 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo of IDV with RTV 200 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo of IDV with RTV 400 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo of both IDV and RTV
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: IDV-RTV regimens
Number of subjects: 73
Study: 31257177

Group type: EXPERIMENTAL
Intervention: Trastuzumab duocarmazine (1.2 mg/kg recommended phase 2 dose)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Trastuzumab duocarmazine
Number of subjects: 185